title: Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants.
abstract: OBJECTIVE
  To evaluate the effect of systemic prednisolone as an adjunct to conventional treatment with beta2-agonist, respiratory support, and fluid replacement in hospitalized infants <24 months of age with respiratory syncytial virus (RSV) infection.
  
  
  METHODS
  The study was randomized, double-blind, and placebo-controlled. During the winter of 1995-1996, 147 infants <2 years of age, hospitalized with RSV infection, were allocated to treatment with either systemic prednisolone mixture 2 mg/kg daily or placebo for 5 days.
  
  
  METHODS
  The acute effect variables were duration of stay in hospital, use of medicine, and supportive measures while in hospital. At follow-up 1 month after discharge, the acute effect variables were duration of illness, start in day care center, morbidity, and use of medicine. At follow-up 1 year after discharge, the acute effect variables were morbidity, use of medicine, and skin prick tests with allergens.
  
  
  RESULTS
  Prednisolone treatment had no effect on any of the outcome measures.
  
  
  CONCLUSIONS
  Our randomized prospective study in infants hospitalized with acute RSV infection showed no effect of systemic prednisolone treatment either in the acute state of RSV infection, nor in the follow-up 1 month and 1 year after admission to hospital. We find our results in agreement with the largest studies reported earlier; therefore, corticosteroid, whether by the systemic route or by inhalation, should not be prescribed to infants with RSV infection.
authors.affiliation: Departments of Pediatrics, Gentofte Hopsital, Gentofte, Denmark. intersus@dadlnet.dk
authors.forename: S M
authors.initials: SM
authors.lastname: Bülow
authors.forename: M
authors.initials: M
authors.lastname: Nir
authors.forename: E
authors.initials: E
authors.lastname: Levin
authors.forename: B
authors.initials: B
authors.lastname: Friis
authors.forename: L L
authors.initials: LL
authors.lastname: Thomsen
authors.forename: J E
authors.initials: JE
authors.lastname: Nielsen
authors.forename: J C
authors.initials: JC
authors.lastname: Holm
authors.forename: T
authors.initials: T
authors.lastname: Moller
authors.forename: M E
authors.initials: ME
authors.lastname: Bonde-Hansen
authors.forename: H E
authors.initials: HE
authors.lastname: Nielsen
mesh_terms: D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007902:Length of Stay / Q000706:statistics & numerical data; D016015:Logistic Models; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone